Navigation Links
Researchers present new findings for novel pancreatic cancer vaccine
Date:5/22/2012

CLEVELAND A novel pancreatic cancer vaccine shows promise in improving survival when added to standard treatment, according to new research out of University Hospitals Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine. The Phase 2 data was presented today (embargoed 11:00 am ET) at the Annual Meeting of the Society for Surgery of the Alimentary Tract, part of Digestive Disease Week in San Diego.

In the plenary session titled "Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study" (Tuesday, May 22, 8:00 a.m. PT Abstract # 028), Jeffrey Hardacre, MD, lead investigator, presented the updated data. The multi-site, nationwide study involved 70 patients with resected pancreatic cancer and suggests improvement in 12-month disease-free and overall survival.

"Pancreatic cancer is a deadly disease with long-term survival less than 5%," says Dr. Hardacre, surgical oncologist with UH Case Medical Center and Associate Professor at Case Western Reserve University School of Medicine. "Better treatments are needed to improve survival and we are encouraged by the promising results of this vaccine therapy."

The vaccine, known as Algenpantucel-L, is unique from other approaches in that it is designed to trigger the patient's own immune system to destroy cancer cells. Algenpantucel-L, developed by NewLink Genetics Corporation, was added to standard adjuvant therapy for patients who have successfully undergone pancreatic surgical resection.

A pivotal, nationwide Phase 3 study of the vaccine, also led in part by Dr. Hardacre, has begun and will involve up to 722 patients.

Cancer of the pancreas is the fourth leading cause of cancer death in the United States, killing more than 35,000 Americans each year. Pancreatic cancer is characteristically aggressive with non-specific initial symptoms, making it difficult to diagnose early. Conventional therapies have little impact on prognosis and disease outcome. Surgical resection of the tumor is currently the only chance for a cure. Without resection, overall median survival is four to six months with an estimated five-year survival rate of 0.4 percent to 5 percent.

"Patients with pancreatic cancer have limited options and there have been few advances for this lethal disease in recent years," says Stan Gerson, MD, Director of the UH Seidman Cancer Center and the Case Comprehensive Cancer Center at Case Western Reserve University. "We are proud that Jeff and our cancer center have played such a significant role in investigating this promising new treatment option."


'/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
216-844-5158
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 19, 2017 , ... PAPA Healthcare, Inc. announced today, the ... Healthcare helps fill gaps, provide essential insights, and improve productivity.” The story ... leveraging PAPA Healthcare’s post-acute productivity and analytics solutions. , St. Vincent’s Home Infusion ...
(Date:9/19/2017)... BETHESDA, MD (PRWEB) , ... September 19, 2017 ... ... of Environmental Compliance and Safety for the President’s Malaria Initiative (PMI) Africa ... of USAID’s Innovation to Action Award. , The Innovation to Action Award, ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... of its national Swirl: A Wine Tasting Event series on Thursday, October 26, ...
(Date:9/19/2017)... ... 2017 , ... The American College of Lifestyle Medicine ... formed Corporate Roundtable, a group of individuals and organizations whose collective vision is ... Ranch is a unique collection of lifestyle-based immersion vacation settings and programs on ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... issued a rallying cry to Americans to watch for the discomforts and hidden ... young athletes to senior citizens, everyone is at risk for developing fungal infections ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 2017 NeuroRx, a clinical stage biopharma company developing ... (ASIB), has been granted Fast Track status by the US ... (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company ... this sequential therapy targeting patients who are admitted to Emergency ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months after ... is pleased to announce the appointment of three new ... Wynne , Dominic Jones-Phillips and James ... Tammy Wynne ... of market access writers. She has over ten years, ...
(Date:8/31/2017)... 2017 PM360,s annual Innovations Issue, published ... latest innovations happening across the industry. Established six years ... on providing a comprehensive look at the newest and ... most innovative companies, startups, divisions, products, services, and strategies ... "Everyone in this industry wants to do better—in ...
Breaking Medicine Technology: